Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

human osteosarcoma cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Amine N-methyltransferase (4) Apoptosis (8) Autophagy (4) Cannabinoid Receptor (1) Caspase (1) CD44 (1) CD47 (1) CDK (4) Clathrin (1) COX (3) Cytochrome P450 (2) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (2) Drug Derivative (1) Dynamin (1) E1/E2/E3 Enzyme (1) EGFR (1) Emopamil Binding Protein (1) Endogenous Metabolite (2) ERK (2) Ferroptosis (1) G-quadruplex (1) HIF/HIF Prolyl-Hydroxylase (1) IGF-1R (1) IMPDH (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (2) MDM-2/p53 (1) mGluR (1) Mitophagy (2) MMP (1) mTOR (3) P-glycoprotein (1) PDK-1 (1) Phosphatase (1) PI3K (3) Protein Arginine Deiminase (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (3) RIBOTAC (1) Transmembrane Glycoprotein (2) VD/VDR (1) VEGFR (3) Wee1 (2) Wnt (2) β-catenin (3)
By Research Areas:	Cancer (27) Infection (1) Inflammation/Immunology (13) Metabolic Disease (6) Neurological Disease (4)

By Targets:

Akt (3)

Amine N-methyltransferase (4)

Apoptosis (8)

Autophagy (4)

Cannabinoid Receptor (1)

Caspase (1)

CD44 (1)

CD47 (1)

CDK (4)

Clathrin (1)

COX (3)

Cytochrome P450 (2)

Dihydroorotate Dehydrogenase (1)

DNA/RNA Synthesis (2)

Drug Derivative (1)

Dynamin (1)

E1/E2/E3 Enzyme (1)

EGFR (1)

Emopamil Binding Protein (1)

Endogenous Metabolite (2)

ERK (2)

Ferroptosis (1)

G-quadruplex (1)

HIF/HIF Prolyl-Hydroxylase (1)

IGF-1R (1)

IMPDH (1)

Integrin (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JNK (2)

MDM-2/p53 (1)

mGluR (1)

Mitophagy (2)

MMP (1)

mTOR (3)

P-glycoprotein (1)

PDK-1 (1)

Phosphatase (1)

PI3K (3)

Protein Arginine Deiminase (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reference Standards (3)

RIBOTAC (1)

Transmembrane Glycoprotein (2)

VD/VDR (1)

VEGFR (3)

Wee1 (2)

Wnt (2)

β-catenin (3)

By Research Areas:

Cancer (27)

Infection (1)

Inflammation/Immunology (13)

Metabolic Disease (6)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0153

Naringin Maximum Cited Publications 24 Publications Verification Naringoside	Cytochrome P450 Autophagy Mitophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities. Naringin also inhibits proliferation and invasion and induces apoptosis in human osteosarcoma cells by inhibiting zinc finger E-box binding homeobox 1 (Zeb1) .

HY-17372

Rofecoxib 5 Publications Verification MK 966	COX	Inflammation/Immunology Cancer
Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).

HY-P99126

Anti-Mouse/Human CD44 Antibody (IM7) 2 Publications Verification	Transmembrane Glycoprotein CD44	Inflammation/Immunology Cancer
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma .

HY-164561

TASIN-30 1 Publications Verification	Emopamil Binding Protein Ferroptosis Apoptosis	Cancer
TASIN-30 is a selective EBP inhibitor with an EC₅₀ of 0.097 μM. TASIN-30 blocks the production of 7-dehydrocholesterol (7-DHC) and downstream cholesterol biosynthesis processes. TASIN-30 depletes downstream sterols, disrupts the integrity of lipid rafts in tumor cells, accelerates intracellular cholesterol consumption, and inhibits tumor cell proliferation. TASIN-30 induces ferroptosis and apoptosis by reducing 7-DHC levels and increasing phospholipid peroxidation. TASIN-30 achieves tumor suppression in nude mice with osteosarcoma. TASIN-30 can be used in cancer-related research such as colorectal cancer and osteosarcoma .

HY-151500

JBSNF-000028 free base	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-N0819

Raddeanin A 1 Publications Verification	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK	Neurological Disease Inflammation/Immunology Cancer
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .

HY-P990858

Anti-CD47 Antibody (B6.H12)	CD47	Cancer
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma .

HY-32341

Seocalcitol 2 Publications Verification EB 1089	VD/VDR	Cancer
Seocalcitol is a vitamin D analog, binds vitamin D receptor protein from human osteosarcoma MG-63 cells with K_d of 0.27 nM.

HY-151500B

JBSNF-000028 hydrochloride	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-119715

AG-012986	CDK Apoptosis	Inflammation/Immunology Cancer
AG-012986 is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-109569

Vitamin K2	Autophagy Apoptosis Interleukin Related	Metabolic Disease Inflammation/Immunology Cancer
Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma .

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .

HY-N0153R

Naringin (Standard) Maximum Cited Publications 24 Publications Verification Naringoside (Standard)	Endogenous Metabolite Cytochrome P450 Mitophagy Autophagy Reference Standards	Inflammation/Immunology Cancer
Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities. Naringin also inhibits proliferation and invasion and induces apoptosis in human osteosarcoma cells by inhibiting zinc finger E-box binding homeobox 1 (Zeb1) .

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR	Metabolic Disease Cancer
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .

HY-169296

IMPDH2-IN-4	IMPDH	Cancer
IMPDH2-IN-4 (Compound 2d) is a selective IMPDH2 inhibitor with a K_i,app value of 1.8 μM. IMPDH2-IN-4 exhibits anti-cancer activity against osteosarcoma. IMPDH2-IN-4 can be used in research related to osteosarcoma .

HY-151500A

JBSNF-000028 TFA	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 TFA can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 TFA exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 TFA can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-15476

VU 0364439	mGluR HIF/HIF Prolyl-Hydroxylase PDK-1 VEGFR	Neurological Disease
VU 0364439 is a mGlu4 positive allosteric modulator with an EC₅₀ of 19.8 nM. VU 0364439 modulates the GRM4/CBX4/HIF-1α signaling pathway by enhancing GRM4-CBX4 interaction. VU 0364439 can be used for the research of parkinson’s disease .

HY-151500C

JBSNF-000028	Amine N-methyltransferase	Metabolic Disease
JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

HY-17372S

Rofecoxib-d5	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Rofecoxib-d₅ is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .

HY-P10775A

BT1769 acetate	MMP	Cancer
BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K_d value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research .

HY-157126

Pterostilbene-isothiocyanate PTER-ITC	β-catenin	Cancer
Pterostilbene-isothiocyanate (PTER-ITC) exhibits potent anticancereffects in vitro. Pterostilbene-isothiocyanate against human osteosarcoma cells by abrogating the β-catenin/TCF-4 interaction .

HY-N8498

GKK1032B	Apoptosis	Cancer
GKK1032B is an alkaloid compound that can be found in endophytic fungus Penicillium sp. GKK1032B can induce the apoptosis of human osteosarcoma MG63 cells through caspase pathway activation .

HY-17372R

Rofecoxib (Standard) MK 966 (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Rofecoxib (Standard) is the analytical standard of Rofecoxib. This product is intended for research and analytical applications. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).

HY-163518

Antitumor agent-153	E1/E2/E3 Enzyme	Cancer
Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity .

HY-N0819R

Raddeanin A (Standard)	Reference Standards Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK	Neurological Disease Inflammation/Immunology Cancer
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.

HY-P992055

Anti-ITGB1 Antibody AIIB2	Integrin Caspase Apoptosis	Neurological Disease Cancer
Anti-ITGB1 Antibody (AIIB2) is a monoclonal antibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the ITGB1 subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma .

HY-183980

MJ-NR-27	RIBOTAC G-quadruplex DNA/RNA Synthesis	Cancer
MJ-NR-27 is a bifunctional small molecule of ribonuclease-targeting chimera (RIBOTAC) that targets NRAS mRNA containing a G-quadruplex structure. MJ-NR-27 uses RNase L ligand 3 (HY-177030) as the RNase L ligand, RNA binder 4 (HY-183981) as the RNA binder, and Bis-PEG3-acid (HY-126891) as the linker. MJ-NR-27 achieves target RNA degradation by recruiting ribonuclease RNase L, and significantly induces morphological changes in tumor cells. MJ-NR-27 can be used in cancer research .

HY-182746

RG7388-PEG3-Click-F	MDM-2/p53 Drug Derivative	Cancer
RG7388-PEG3-Click-F is a fluorinated analog of the MDM2 inhibitor RG7388 (HY-15676), with an IC₅₀ of 16.8 nM against MDM2. [ ¹⁸F]RG7388-PEG3-Click-F exhibits high uptake and specificity in MDM2-expressing myeloma cells, and can be used for non-invasive assessment of MDM2 protein expression levels in tumors .

HY-182634

NCGC00063279	DNA/RNA Synthesis Phosphatase	Cancer
NCGC00063279 is a reversible Werner Syndrome Helicase-Nuclease (WRN) helicase inhibitor with modest selectivity over BLM and FANCJ helicases, and does not inhibit WRN exonuclease activity at active concentrations. NCGC00063279 inhibits Hematopoietic Protein Tyrosine Phosphatase (HePTP) and reduces proliferation of cancer cells. NCGC00063279 can be used for the research of osteosarcoma .

HY-182470

AG-012986 dihydrochloride	CDK
AG-012986 (dihydrochloride) is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC₅₀ values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 (dihydrochloride) causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 (dihydrochloride) induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 (dihydrochloride) exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 (dihydrochloride) can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-P992430

OI-3	Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology Cancer
OI-3 is a monoclonal antibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with ²¹²Pb to form ²¹²Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma .

HY-181449

CAY10729	Protein Arginine Deiminase	Inflammation/Immunology
CAY10729 (Compound 21) is a selective PAD2 inhibitor. CAY10729 inhibits neutrophil extracellular trap formation .

HY-182550

Indoluidin D	Dihydroorotate Dehydrogenase	Cancer
Indoluidin D is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with a human DHODH IC₅₀ of 210 nM. Indoluidin D selectively inhibits human DHODH activity, with induced effects rescuable by orotic acid. Indoluidin D promotes myeloid differentiation and inhibits cancer cell proliferation. Indoluidin D can be used for the research of acute promyelocytic leukemia .

HY-181933

Clathrin-IN-5	Clathrin Dynamin	Infection
Clathrin-IN-5 (Compound 9) is a Clathrin N-terminal domain-Amphiphysin protein-protein interaction inhibitor with an IC₅₀ of 2.77 μM. Clathrin-IN-5 inhibits the protein-protein interaction between the clathrin N-terminal domain and amphiphysin. Clathrin-IN-5 inhibits clathrin-mediated endocytosis with an IC₅₀ of 4.6 μM. Clathrin-IN-5 inhibits the GTPase activity of Dynamin I with an IC₅₀ of 29.7 μM .

Cat. No.	Product Name	Target	Research Area